158 related articles for article (PubMed ID: 25441760)
1. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
4. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer: BRCA and beyond.
Rios J; Puhalla S
Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
[TBL] [Abstract][Full Text] [Related]
6. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
8. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
9. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
Plummer R
Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
[TBL] [Abstract][Full Text] [Related]
11. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
13. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
14. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Gaziev AI
Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
del Rivero J; Kohn EC
Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Powell C; Mikropoulos C; Kaye SB; Nutting CM; Bhide SA; Newbold K; Harrington KJ
Cancer Treat Rev; 2010 Nov; 36(7):566-75. PubMed ID: 20409643
[TBL] [Abstract][Full Text] [Related]
17. A snapshot of chemoresistance to PARP inhibitors.
Chiarugi A
Trends Pharmacol Sci; 2012 Jan; 33(1):42-8. PubMed ID: 22055391
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
19. [PARP inhibitors and breast cancer: update and perspectives].
Gonçalves A
Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
[TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Cinefra M; D'Amico M; Mazzoni E; Marino A; Sponziello F; Morelli F; Lombardi L; Silvestris N; Cinieri S
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S83-9. PubMed ID: 22443171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
